Literature DB >> 19190593

Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4.

David W McDermott1, Martin G Sanda.   

Abstract

This commentary discusses the re-analysis of the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4), which had previously shown a modest but significant survival benefit of prostatectomy over watchful waiting. In the re-analysis, patients allocated to watchful waiting experienced a significantly decreased health-related quality of life (HRQOL) at 6-8 years after randomization, compared with those who underwent radical prostatectomy. HRQOL differences between treatment arms in the first 5 years after randomization were limited to worse erectile dysfunction among patients randomized to prostatectomy. These findings indicate that watchful waiting might be associated with greater late deterioration in select domains of HRQOL than is prostatectomy. In addition, patients randomized to watchful waiting who received androgen deprivation therapy (ADT) reported a lower sense of well-being, more-depressed mood, and a lower self-assessed quality of life compared with those who did not receive ADT, which indicates that ADT might adversely affect HRQOL in this patient population.

Entities:  

Year:  2009        PMID: 19190593     DOI: 10.1038/ncpuro1314

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN: 1743-4270


  7 in total

1.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

2.  Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.

Authors:  Arnold L Potosky; Bryce B Reeve; Limin X Clegg; Richard M Hoffman; Robert A Stephenson; Peter C Albertsen; Frank D Gilliland; Janet L Stanford
Journal:  J Natl Cancer Inst       Date:  2002-03-20       Impact factor: 13.506

3.  Quality of life after radical prostatectomy or watchful waiting.

Authors:  Gunnar Steineck; Fred Helgesen; Jan Adolfsson; Paul W Dickman; Jan-Erik Johansson; Bo Johan Norlén; Lars Holmberg
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

4.  Quality of life and satisfaction with outcome among prostate-cancer survivors.

Authors:  Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

5.  Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.

Authors:  Eva Johansson; Anna Bill-Axelson; Lars Holmberg; Erik Onelöv; Jan-Erik Johansson; Gunnar Steineck
Journal:  Eur Urol       Date:  2008-09-02       Impact factor: 20.096

Review 6.  Active surveillance for early-stage prostate cancer: review of the current literature.

Authors:  Marc A Dall'Era; Matthew R Cooperberg; June M Chan; Benjamin J Davies; Peter C Albertsen; Laurence H Klotz; Christopher A Warlick; Lars Holmberg; Donald E Bailey; Meredith E Wallace; Philip W Kantoff; Peter R Carroll
Journal:  Cancer       Date:  2008-04-15       Impact factor: 6.860

7.  Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE.

Authors:  Shelley A Arredondo; Tracy M Downs; Deborah P Lubeck; David J Pasta; Stefanie J Silva; Katrine L Wallace; Peter R Carroll
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450

  7 in total
  1 in total

1.  Radical prostatectomy versus deferred treatment for localised prostate cancer.

Authors:  Robin Wm Vernooij; Michelle Lancee; Anne Cleves; Philipp Dahm; Chris H Bangma; Katja Kh Aben
Journal:  Cochrane Database Syst Rev       Date:  2020-06-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.